Saturday 17 October 2026
Export MAZE’s income statement to Excel — free account
Maze Therapeutics, Inc.
MAZE Healthcare Biotechnology
Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million. In the quarter to June 2026, EPS grew 1.30% and free cash flow grew 50.2%, each against the same quarter a year earlier.
27.53
0.05
+0.18%
Follow MAZE
Maze Therapeutics, Inc. (MAZE) P/E ratio
Maze Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.0× (January 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 1.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Sep 2024 | 1.0× | 0.00% |
| Jun 2024 | 1.0× | — |
Against its own ten years
Low 0.0×
High 1.0×
Ten-year median
0.0×
Current reading's percentile
76
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QURE uniQure N.V. compare | n/m |
| STOK Stoke Therapeutics, Inc. compare | n/m |
| ABSI Absci Corporation compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)